These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 15690162)
1. [TNFalpha inhibitors in the treatment of uveitis]. Greiner K; Plskova J Ophthalmologe; 2005 Apr; 102(4):335-40. PubMed ID: 15690162 [TBL] [Abstract][Full Text] [Related]
2. Drug-induced inflammation in patients on TNFα inhibitors. Cunningham ET; Pasadhika S; Suhler EB; Zierhut M Ocul Immunol Inflamm; 2012 Feb; 20(1):2-5. PubMed ID: 22324894 [No Abstract] [Full Text] [Related]
3. [The treatment of recurrent uveitis with TNF-alpha inhibitors]. Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524 [TBL] [Abstract][Full Text] [Related]
4. TNFalpha-blocking agents or conventional immunosuppressive drugs in the therapy of children with uveitis? - an evidence based approach. Winterhalter S; Niehues T Klin Padiatr; 2008; 220(6):342-7. PubMed ID: 18949668 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults. Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430 [TBL] [Abstract][Full Text] [Related]
7. [Anti-TNF-α treatment for uveitis. Analysis of the current situation]. Pleyer U; Mackensen F; Winterhalter S; Stübiger N Ophthalmologe; 2011 Jan; 108(1):13-20. PubMed ID: 21181169 [TBL] [Abstract][Full Text] [Related]
8. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607 [TBL] [Abstract][Full Text] [Related]
9. Anti-tumor necrosis factor-α therapy in uveitis. Cordero-Coma M; Sobrin L Surv Ophthalmol; 2015; 60(6):575-89. PubMed ID: 26164735 [TBL] [Abstract][Full Text] [Related]
10. [How to optimize the antiTNF alpha therapy in spondylitis?]. Castro Villegas Mdel C; Escudero Contreras A; Miranda García MD; Collantes Estévez E Reumatol Clin; 2012 Mar; 8 Suppl 1():S26-31. PubMed ID: 22418285 [TBL] [Abstract][Full Text] [Related]
11. Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis. Gallego-Pinazo R; Dolz-Marco R; Martínez-Castillo S; Arévalo JF; Díaz-Llopis M Inflamm Allergy Drug Targets; 2013 Feb; 12(1):38-45. PubMed ID: 23441991 [TBL] [Abstract][Full Text] [Related]
12. Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review. Calvo-Río V; de la Hera D; Blanco R; Beltrán-Catalán E; Loricera J; Cañal J; Ventosa J; Cifrián JM; Ortiz-Sanjuán F; Rueda-Gotor J; González-Vela MC; González-López M; González-Gay MA Clin Exp Rheumatol; 2014; 32(6):864-8. PubMed ID: 25288110 [TBL] [Abstract][Full Text] [Related]
13. Uncovering the risks of immunosuppressive therapy in patients with uveitis. Goldstein DA Arch Ophthalmol; 2009 Jun; 127(6):799-800. PubMed ID: 19506201 [No Abstract] [Full Text] [Related]